Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

Study Overview
=================
Brief Summary
-----------------
Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.

Official Title
-----------------
Renal Cell Cancer Registry in Latin American Clinical-phatological Characterization and Outcomes of Renal Cell Carcinoma in Latin America

Conditions
-----------------
Kidney Neoplasms

Intervention / Treatment
-----------------
* Other: Observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 18 years of age; Proven histology of renal cell carcinoma (any subtype); Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center; Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome. Exclusion Criteria: Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with pathological diagnosis of renal cell carcinoma<br>Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period. | Other: Observational study<br>* This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Build a real-life renal cell cancer database in Brazil and Latin America |  | 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sociodemographic characteristics checklist | Describe sociodemographic characteristics: age at diagnosis, race, education, family income, occupation, personal habits, family history, comorbidities, treatment funding (public or private), treatment institution (public, private or philanthropic). | 2022 | 
| Clinicopathological characteristics of patients with renal cell cancer checklist | date of onset of symptoms, pre-treatment symptoms, histology, clinical and pathological stage, performance status, tests used in staging, date of diagnosis, site of metastases, complications clinics. | 2022 | 
| Characteristics of systemic treatment checklist | date of biopsy; dates, type and lines of drug treatment. | 2022 | 
| Time between diagnosis and start of treatment. | Characteristics of systemic treatment checklist | 2022 | 
| Causes of delay or discontinuation of each treatment checklist | Characteristics of systemic treatment | 2022 | 
| Progression-free survival in each therapeutic line |  | 2022 | 
| Overall survival |  | 2022 |